Clinical TrialsThe revised trial design for belapectin's Phase 2b study increases the likelihood of success, as it now has a lower statistical hurdle to meet.

Financial StabilityGalectin's cash runway extends beyond the key data readout, providing financial flexibility before advancing belapectin into Phase 3.

Trial EnrollmentThe NAVIGATE trial was over-enrolled by 42 patients, reflecting positive investigator response and potentially enhancing the trial's statistical power.

Bears Say

Clinical TrialsThe second Phase 2b study of belapectin failed to reach statistical significance on the primary endpoint.

Investor SentimentInvestor sentiment on GALT is now rather poor, given this is the second Phase 2b trial to miss its primary endpoint.

Stock PerformanceThe base case scenario is GALT trades sideways for the foreseeable future, resulting in a downgrade to Neutral from Buy.

---

Financials

Annual

Income Statement >

Ownership Overview

28.19% Insiders

4.66% Mutual Funds

<0.01% Other Institutional Investors

62.66% Public Companies and Individual Investors

Detailed Ownership Overview >

Risk Analysis

Main Risk Category

Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

Detailed Risk Analysis >

GALT FAQ

What was Galectin Therapeutics (GALT)’s price range in the past 12 months?

Galectin Therapeutics (GALT) lowest stock price was $0.73 and its highest was $4.27 in the past 12 months.

What is Galectin Therapeutics (GALT)’s market cap?

Galectin Therapeutics (GALT)’s market cap is $77.89M.

When is Galectin Therapeutics (GALT)’s upcoming earnings report date?

Galectin Therapeutics (GALT)’s upcoming earnings report date is Mar 27, 2025 which is in 64 days.

How were Galectin Therapeutics (GALT)’s earnings last quarter?

Galectin Therapeutics (GALT) released its earnings results on Nov 14, 2024. The company reported -$0.18 earnings per share for the quarter, beating the consensus estimate of -$0.2 by $0.02.

Is Galectin Therapeutics (GALT) overvalued?

According to Wall Street analysts Galectin Therapeutics (GALT)’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Galectin Therapeutics (GALT) pay dividends?

Galectin Therapeutics (GALT) does not currently pay dividends.

What is Galectin Therapeutics (GALT)’s EPS estimate?

Galectin Therapeutics (GALT)’s EPS estimate is -0.16.

How many shares outstanding does Galectin Therapeutics (GALT) have?

Galectin Therapeutics (GALT) has 62,308,075 shares outstanding.

What happened to Galectin Therapeutics (GALT)’s price movement after its last earnings report?

Galectin Therapeutics (GALT) reported an EPS of -$0.18 in its last earnings report, beating expectations of -$0.2. Following the earnings report the stock price went down -5.172%.

Which hedge fund is a major shareholder of Galectin Therapeutics (GALT)?

Currently, no hedge funds are holding shares in GALT

---

Galectin Therapeutics Stock Smart Score

Unlock Smart Score

Fundamentals

Return on Equity

48.74%

Trailing 12-Months

Asset Growth

30.72%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Galectin Therapeutics (GALT)

Galectin Therapeutics, Inc. is a biotechnology company, which engages in drug research and development to create new therapies for fibrotic disease, severe skin disease, and cancer. Its programs targets the development of carbohdrate molecules which offers offer alternative options to larger market segments. The company was founded by James C. Czirr and Anatole A. Klyosov on July 10, 2000 and is headquartered in Norcross, GA.

---